Coherus Oncology
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CHRS and other ETFs, options, and stocks.About CHRS
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI.
CEODenny M. Lanfear
CEODenny M. Lanfear
Employees228
Employees228
HeadquartersRedwood City, California
HeadquartersRedwood City, California
Founded2010
Founded2010
Employees228
Employees228
CHRS Key Statistics
Market cap261.08M
Market cap261.08M
Price-Earnings ratio-1.36
Price-Earnings ratio-1.36
Dividend yield—
Dividend yield—
Average volume5.15M
Average volume5.15M
High today$2.37
High today$2.37
Low today$2.13
Low today$2.13
Open price$2.29
Open price$2.29
Volume1.92M
Volume1.92M
52 Week high$2.62
52 Week high$2.62
52 Week low$0.71
52 Week low$0.71
Stock Snapshot
Coherus Oncology(CHRS) stock is priced at $2.18, giving the company a market capitalization of 261.08M. It carries a P/E multiple of -1.36.
During the trading session on 2026-01-31, Coherus Oncology(CHRS) shares reached a daily high of $2.37 and a low of $2.13. At a current price of $2.18, the stock is +2.3% higher than the low and still -8.1% under the high.
Trading activity shows a volume of 1.92M, compared to an average daily volume of 5.15M.
The stock's 52-week range extends from a low of $0.71 to a high of $2.62.
The stock's 52-week range extends from a low of $0.71 to a high of $2.62.
Analyst ratings
83%
of 6 ratingsBuy
83.3%
Hold
16.7%
Sell
0%
People also own
Based on the portfolios of people who own CHRS. This list is generated using Robinhood data, and it’s not a recommendation.